Armata AP-PA02-201
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection. ARMATA AP-PA02-201
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Bronchiectasis
Study Purpose
The first study of AP PA02 was recently conducted in subjects with cystic fibrosis (Study AP PA02 101). This small study is completed, with a limited amount of data, so risks and side effects are not fully known. In this study, all side effects reported were mild or moderate and self-limited. The main purpose of this study is to learn how well the study drug works, how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone.
Who Can Participate
Age: 18 and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20231258
- StudyID: 2023-01219
- ClinicalTrials.gov: NCT05616221
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422